Recursion Pharmaceuticals (NASDAQ:RXRX) CEO Najat Khan Sells 22,408 Shares

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Najat Khan sold 22,408 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $3.52, for a total value of $78,876.16. Following the completion of the sale, the chief executive officer directly owned 2,072,890 shares in the company, valued at $7,296,572.80. This trade represents a 1.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Recursion Pharmaceuticals Price Performance

Shares of Recursion Pharmaceuticals stock opened at $3.16 on Friday. The stock has a 50 day moving average of $3.30 and a 200 day moving average of $3.33. Recursion Pharmaceuticals, Inc. has a 12 month low of $2.77 and a 12 month high of $7.18. The firm has a market cap of $1.69 billion, a PE ratio of -3.04 and a beta of 1.07. The company has a current ratio of 5.03, a quick ratio of 5.03 and a debt-to-equity ratio of 0.01.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). The firm had revenue of $7.67 million during the quarter, compared to the consensus estimate of $10.97 million. Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%.During the same period in the previous year, the firm earned ($0.41) EPS. On average, research analysts expect that Recursion Pharmaceuticals, Inc. will post -0.92 EPS for the current fiscal year.

Institutional Trading of Recursion Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RXRX. State Street Corp increased its holdings in shares of Recursion Pharmaceuticals by 38.7% during the 4th quarter. State Street Corp now owns 25,333,888 shares of the company’s stock valued at $103,616,000 after purchasing an additional 7,064,963 shares in the last quarter. Norges Bank purchased a new stake in shares of Recursion Pharmaceuticals in the fourth quarter valued at approximately $23,473,000. ARK Investment Management LLC raised its stake in shares of Recursion Pharmaceuticals by 11.2% during the 4th quarter. ARK Investment Management LLC now owns 37,316,856 shares of the company’s stock worth $152,626,000 after buying an additional 3,771,357 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Recursion Pharmaceuticals during the 1st quarter worth approximately $7,370,000. Finally, Millennium Management LLC purchased a new position in shares of Recursion Pharmaceuticals during the 4th quarter valued at approximately $6,118,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Wall Street Zen raised shares of Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Friday, July 17th. Finally, Morgan Stanley set a $5.30 price target on Recursion Pharmaceuticals in a research report on Monday, August 17th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $8.06.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.